Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

WHO gives Cervarix green light for use in developing nations

July 10, 2009 Research and Development, Sales and Marketing Cervarix, vaccines

News

NICE to reconsider GSK’s Tyverb

July 9, 2009 Research and Development, Sales and Marketing GSK, NICE, Tyverb

NICE is to reconsider Tyverb under its new lenient approach for end-of-life drugs, after GSK appealed its previous rejection of …
News

Writing on the wall for ‘pay to delay’ generics deals

July 9, 2009 Research and Development, Sales and Marketing FDA, US, generics

Deals allowing US pharma companies to pay generics competitors to delay the launch of rival products should be ended, according …
News

Genzyme’s woes are a boost for Shire and Protalix

July 9, 2009 Research and Development, Sales and Marketing FDA, Genzyme, US

The contamination problems at a plant used by Genzyme to manufacture a drug for Gaucher disease have prompted the US …
News

Europe launches pharma competition crackdown

July 8, 2009 Research and Development Europe, generics

The European Union's competition watchdog has declared a crackdown on pharma industry competition, promising scrutiny of deals which it says …
News
Eisai's new European HQ in Hatfield, Hertfordshire

Eisai opens new European HQ in the UK

July 8, 2009 Manufacturing and Production, Research and Development, Sales and Marketing Eisai, Europe, HQ

Eisai has officially opened its new European headquarters in the UK, its biggest-ever single capital investment that will bring teams …
Feature
UCB's new biologics research centre in Slough

UCB opens new UK biologics research centre

July 8, 2009 Research and Development UCB

 UCB has officially opened its new biologics research centre in the UK, representing an investment of £25 million for the …
News

Sanofi moves to quell Lantus safety concerns

July 7, 2009 Research and Development, Sales and Marketing Lantis, Sanofi-Aventis, diabetes

Sanofi-Aventis has rejected claims of a possible connection between its diabetes treatment Lantus and cancer. The possible link was reported …
News

Depression warnings for Chantix and Zyban

July 7, 2009 Research and Development, Sales and Marketing Chantix, FDA, US, drug safety

Pfizer and GSK's smoking cessations drugs will have to carry strong warnings of depression and other mental health adverse events …
News

Roche’s ABPI exit – a deliberate snub?

July 3, 2009 Research and Development, Sales and Marketing ABPI, Roche

 By Nicola O’BrienRoche is yet to explain its controversial exit from the ABPI, but the company seems determined to make …
News

Asia Pacific vaccines market requires flexible, targeted portfolios

July 2, 2009 Research and Development, Sales and Marketing Asia, vaccines

Spanning one third of the globe's circumference and home to more than half of the world's population, the Asia Pacific …
News

Onglyza and Cimzia recommended by CHMP

July 2, 2009 Research and Development, Sales and Marketing AZ, BMS, EMEA, Europe, Ongylza

Bristol-Myers Squibb andAstraZeneca's type II diabetes treatment Onglyza is among the brands to have received positive opinions from the Committee …
News

Pfizer halts Sutent colon cancer trial

July 2, 2009 Research and Development, Sales and Marketing Cancer, Pfizer, Sutent

Pfizer has halted a phase III trial for its oncology hope Sutent, after it failed to show significant improvement in …
News

Rovi wins Spanish contract for flu vaccines

July 1, 2009 Manufacturing and Production, Research and Development Europe, Rovi, Spain

News

Sanofi unveils new R&D strategy

July 1, 2009 Research and Development, Sales and Marketing Sanofi-Aventis

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026